annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
Brd. 21 A phase II trial of radiotherapy sandwiched between carboplatin and
docetaxel for stage III, IV, and recurrent endometrial cancer. (Abstract #5029)
M. A. Geller, J. Ivy, R. Ghebre, L. S. Downs, P. L. Judson, L. F. Carson,
A. L. Jonson, K. Dusenbery, M. Boente, P. Argenta
Brd. 22 Treatment outcomes for older women with advanced ovarian cancer: Results
from a phase III clinical trial (GOG182). (Abstract #5030)
W. P. Tew, J. Java, D. Chi, A. Menzin, J. L. Lovecchio, M. A. Bookman,
S. M. Lichtman
Brd. 23 Can elderly patients with recurrent ovarian cancer (ROC) be treated with a
platinum-based doublet? Results from the CALYPSO trial. (Abstract #5031)
J. Kurtz, F. Hilpert, A. Dorum, A. Veillard, L. Elit, M. Buck, E. Petru, N. Reed,
G. Scambia, N. Varsellona
Brd. 24 Defining clinical and statistical improvement in consolidation single-arm
trials in ovarian cancer. (Abstract #5032)
D. R. Spriggs, A. Iasonos, P. Sabbatini, R. E. O’Cearbhaill, H. T. Thaler
Brd. 25 Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated
liposomal doxorubicin (PLD) in patients with advanced ovarian cancer
(AOC): Final analysis of the MITO-2 randomized multicenter trial. (Abstract
#LBA5033)
S. Pignata, G. Scambia, A. Savarese, R. Sorio, E. Breda, F. Legge, V. Gebbia,
P. Musso, C. Gallo, F. Perrone, on behalf of MITO Group
252